Moderna Inc. Common Stock (MRNA)
Stock · NASDAQ · Health Care
$217.55as of 10/16/2026
Price chart
Active signals
MRNA Signal Track Record
How signals performed across all stocks →What MRNA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -1.9% | 44% | October 8, 2026 |
| Bollinger Band Breakdown | 21 | -1.7% | 48% | April 29, 2026 |
| Bollinger Band Breakout | 20 | -1.4% | 45% | September 21, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -6.3% | 40% | December 5, 2025 |
| Any 20-session window (baseline) | -1.8% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 4,700
- Website
- www.modernatx.com/
Fundamentals
- 1-day range
- $217.02$242.29
- Market cap
- $21.50B
- P/E (trailing)
- —
- P/E (forward)
- -53.29
- EPS (trailing)
- $-7.98
- Dividend yield
- —
- Beta
- 1.18
- Avg. volume
- 18.66M
How Moderna Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 20, 2026 · via SEC EDGAR / Finnhub
Forecasts
18 analyst ratings
Moderna Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MRNAModerna Inc. Common Stock$218.01▼ 7.82%Market cap $21.50BP/E —$22.28$227.46
- BNTXBioNTech SE American Depositary Share$87.71▼ 2.76%Market cap $22.91BP/E —$79.52$124
- NBIXNeurocrine Biosciences Inc. Common Stock$135.71▼ 0.91%Market cap $16.25BP/E 19.57$122.14$186.12
- EXELExelixis Inc. Common Stock$62.23▼ 0.95%Market cap $13.12BP/E 17.49$33.76$61.66
- BIIBBiogen Inc. Common Stock$232.65▼ 1.15%Market cap $30.48BP/E 42.27$138$238.24
- HALOHalozyme Therapeutics Inc. Common Stock$121.84▲ 0.27%Market cap $10.17BP/E 32.51$61.23$119.21
- KRYSKrystal Biotech Inc. Common Stock$316.58▼ 4.07%Market cap $9.55BP/E 40.85$181.44$382.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MRNA Moderna Inc. Common Stock | $21.50B | — | $218.01 | ▼ 7.82% | $22.28$227.46 |
| BNTX BioNTech SE American Depositary Share | $22.91B | — | $87.71 | ▼ 2.76% | $79.52$124 |
| NBIX Neurocrine Biosciences Inc. Common Stock | $16.25B | 19.57 | $135.71 | ▼ 0.91% | $122.14$186.12 |
| EXEL Exelixis Inc. Common Stock | $13.12B | 17.49 | $62.23 | ▼ 0.95% | $33.76$61.66 |
| BIIB Biogen Inc. Common Stock | $30.48B | 42.27 | $232.65 | ▼ 1.15% | $138$238.24 |
| HALO Halozyme Therapeutics Inc. Common Stock | $10.17B | 32.51 | $121.84 | ▲ 0.27% | $61.23$119.21 |
| KRYS Krystal Biotech Inc. Common Stock | $9.55B | 40.85 | $316.58 | ▼ 4.07% | $181.44$382.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’benzinga · 10/12/2026
- Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?Yahoo · 10/10/2026
- A COVID Vaccine Stock on the S&P 500 Is Up 600% This YearYahoo · 10/10/2026
- The 1-Minute Market Report October 10, 2026SeekingAlpha · 10/10/2026
- Banking Bellwethers Kick Off Earnings, Fed Chair's Speech In FocusSeekingAlpha · 10/10/2026
- BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine PushYahoo · 10/10/2026
- Why Moderna Stock Surged TodayYahoo · 10/10/2026
- MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine PushYahoo · 10/9/2026
- US Equity Markets End Higher Amid Broad Rally, Strong Mega-Cap GainsYahoo · 10/9/2026
Insider Activity
Insider Actions →- James M. Mock · October 5, 2026 · Option Exercise1.5K
- James M. Mock · October 5, 2026 · Tax Withholding704 @ $190.01
- Stephen Hoge · September 15, 2026 · Option Exercise76.5K @ $12.21
- Stephen Hoge · September 15, 2026 · Sale40.3K @ $146.07
- Stephen Hoge · September 14, 2026 · Option Exercise76.5K @ $12.21
- Stephen Hoge · September 14, 2026 · Sale40.3K @ $144.13
- James M. Mock · September 10, 2026 · Option Exercise19.8K @ $30.96
- James M. Mock · September 10, 2026 · Sale15.0K @ $134.49
- James M. Mock · September 10, 2026 · Sale19.8K @ $134.49
- James M. Mock · September 4, 2026 · Option Exercise11.8K
- James M. Mock · September 4, 2026 · Tax Withholding5.7K @ $148.87
- Shannon Thyme Klinger · September 4, 2026 · Option Exercise11.8K
- Shannon Thyme Klinger · September 4, 2026 · Tax Withholding5.7K @ $148.87
- Shannon Thyme Klinger · September 1, 2026 · Option Exercise3.5K @ $30.96
- Shannon Thyme Klinger · September 1, 2026 · Tax Withholding1.0K @ $140.34
Institutional Ownership
March 31, 2026
- Total shares held
- 348.76M
- Total value held
- $17.55B
- Institutional holders
- 722
- Unknown45.67M
- Unknown29.64M
- Unknown22.87M
- Unknown19.99M
- Unknown18.70M
- Unknown14.86M
- Unknown12.58M
- Unknown9.44M
- Unknown9.21M
- Unknown8.47M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MRNA hits 52-week high after Goldman raises target
The stock reached a new 52‑week high after Goldman Sachs increased its price target, citing upcoming melanoma data. This move aligns with a broader rotation of capital into healthcare names, lifting Moderna by about 6% and pushing the share price near the top of its 52‑week range. Analyst coverage shows an average target of $122.67, while recent commentary highlights interest in cancer vaccine developments.
MRNA hits 52-week high after Goldman raises target. The stock reached a new 52‑week high after Goldman Sachs increased its price target, citing upcoming melanoma data. This move aligns with a broader rotation of capital into healthcare names, lifting Moderna by about 6% and pushing the share price near the top of its 52‑week range. Analyst coverage shows an average target of $122.67, while recent commentary highlights interest in cancer vaccine developments.